The Journal of Neuroimmune Pharmacology recently published a a systematic review of randomized controlled clinical trials announcing cannabinoids are not only safe, but also effective for the treatment of chronic pain. Investigators at Dalhousie University and McGill University looked at 11 different placebo-controlled trials conducted between 2010 and 2014 involving different cannabinoid preparations, like herbal cannabis, liquid and oral cannabis extracts, and a synthetic analog of THC, for the use of pain treatment. They found in most of the studies, cannabinoids were well tolerated by patients and possessed analgesic effects. The authors of the review concluded, "currently available cannabinoids are safe, modestly effective analgesics that provide a reasonable therapeutic option in the management of chronic non-cancer pain."
Other reviews have reported similar findings, and in September, Canadian researchers reported pain patients who consumed herbal cannabis daily for a year effectively reduced their symptoms without increasing serious adverse side effects in comparison to matched controls. This information has been provided by NORML and approved by our Chief Medical Officer. You can also find an abstract of the systematic review here.